1,990 reports of this reaction
4.0% of all CANAGLIFLOZIN reports
#4 most reported adverse reaction
ACUTE KIDNEY INJURY is the #4 most commonly reported adverse reaction for CANAGLIFLOZIN, manufactured by Janssen Pharmaceuticals, Inc.. There are 1,990 FDA adverse event reports linking CANAGLIFLOZIN to ACUTE KIDNEY INJURY. This represents approximately 4.0% of all 49,711 adverse event reports for this drug.
Patients taking CANAGLIFLOZIN who experience acute kidney injury should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACUTE KIDNEY INJURY is moderately reported among CANAGLIFLOZIN users, representing a notable but not dominant share of adverse events.
In addition to acute kidney injury, the following adverse reactions have been reported for CANAGLIFLOZIN:
The following drugs have also been linked to acute kidney injury in FDA adverse event reports:
ACUTE KIDNEY INJURY has been reported as an adverse event in 1,990 FDA reports for CANAGLIFLOZIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACUTE KIDNEY INJURY accounts for approximately 4.0% of all adverse event reports for CANAGLIFLOZIN, making it a notable side effect.
If you experience acute kidney injury while taking CANAGLIFLOZIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.